|
Market Closed -
Other stock markets
|
After hours 22:59:59 | |||
| 0.6980 EUR | +36.59% |
|
0.6910 | -1.00% |
| 07-13 | AB Science to Discontinue Three Masitinib-related Clinical Studies | MT |
| 07-10 | AB Science streamlines its portfolio and refocuses on two molecules |  |
Main competitors
| Dividend Yield (Y) | Dividend Yield (Y+1) | P/E (Y) | Price to Book (Y) | EV / Sales (Y) | EV / EBITDA (Y) | EV / EBIT (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|
 | - | - | - | - | - | - | - | 46.55M | |
| 2.59% | 2.7% | 38.22x | 6.26x | 5.4x | 20.88x | 27.9x | 324B | |
| 1.68% | 1.75% | 23.55x | 1.97x | 3.23x | 11.51x | 18.98x | 68.88B | |
| 2.63% | 2.8% | 16.95x | 1.47x | 2.16x | 7.38x | 8.83x | 8.37B | |
| -.--% | -.--% | 21.5x | 5.72x | 6.1x | 17.23x | 18.02x | 4.32B | |
| 0.74% | 0.75% | 41.13x | 2.48x | 2.36x | 29.57x | 44.11x | 3.83B | |
| -.--% | -.--% | 103.82x | - | - | - | - | 2.68B | |
| 4.02% | 3.47% | 17.6x | 0.77x | 1.39x | 24.82x | 42.49x | 1.07B | |
| Average | 1.67% | 1.64% | 37.54x | 3.11x | 3.44x | 18.56x | 26.72x | 51.62B | |
| Weighted average by Cap. | 2.38% | 2.48% | 35.56x | 5.38x | 4.94x | 19.08x | 26.10x |
- Stock Market
- Stocks
- AB Stock
- Sector AB Science
- Sector dividends
Select your edition
All financial news and data tailored to specific country editions
